Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine the efficacy of cholinesterase inhibitors (ChEIs) in improving the behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer's disease (AD). DATA SOURCES: We searched MEDLINE, Cochrane Registry, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) from 1966 to 2007. We limited our search to English Language, full text, published articles and human studies. DATA EXTRACTION: We included randomized, double-blind, placebo-controlled trials evaluating the efficacy of donepezil, rivastigmine, or galantamine in managing BPSD displayed by AD patients. Using the United States Preventive Services Task Force (USPSTF) guidelines, we critically appraised all studies and included only those with an attrition rate of less than 40%, concealed measurement of the outcomes, and intention to treat analysis of the collected data. All data were imputed into pre-defined evidence based tables and were pooled using the Review Manager 4.2.1 software for data synthesis. RESULTS: We found 12 studies that met our inclusion criteria but only nine of them provided sufficient data for the meta-analysis. Among patients with mild to severe AD and in comparison to placebo, ChEIs as a class had a beneficial effects on reducing BPSD with a standard mean difference (SMD) of -0.10 (95% confidence interval [CI]; -0.18, -0.01) and a weighted mean difference (WMD) of-1.38 neuropsychiatry inventory point (95% CI; -2.30, -0.46). In studies with mild AD patients, the WMD was -1.92 (95% CI; -3.18, -0.66); and in studies with severe AD patients, the WMD was -0.06 (95% CI; -2.12, +0.57). CONCLUSION: Cholinesterase inhibitors lead to a statistical significant reduction in BPSD among patients with AD, yet the clinical relevance of this effect remains unclear.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Lyketsos, C. G., Lopez, O., Jones, B., Fitzpatrick, A. L., Breitner, J., & DeKosky, S. (2002) · JAMA · doi:10.1001/jama.288.12.1475 · Cited by 2,049 · cited 1×
“…increased as dementia-related disability worsened, individuals with mild dementia had a mean total score on the NPI of 5.80 (SD = 12.5), those with moderate dementia had a mean score of 8.8 (SD = 11.10), and those with severe dementia had a mean score of 10.6 (SD = 17.0) (Lyketsos et al 2002).”
InfluentialMcKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03399-7 · Cited by 1,182
Lyketsos, C. G., Steinberg, M., Tschanz, J. T., Norton, M. C., Steffens, D. C., & Breitner, J. C. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.708 · Cited by 1,144
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., & Damaraju, C. V. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08267-3 · Cited by 752
Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.8.1049 · Cited by 744
Donepezil for the Treatment of Agitation in Alzheimer's Disease
Howard, R. J., Juszczak, E., Ballard, C. G., Bentham, P., Brown, R. G., Bullock, R., Burns, A. S., Holmes, C., Jacoby, R., Johnson, T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066583 · Cited by 327
Incontinence and Troublesome Behaviors Predict Institutionalization in Dementia
O'Donnell, B. F., Drachman, D. A., Barnes, H. J., Peterson, K. E., Swearer, J. M., & Lew, R. A. (1992) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/002383099200500108 · Cited by 297 · cited 1×
“They are considered one of the strongest predictors for institutionalization of demented patients (Colerick and George 1986; Steele et al 1990; O’Donnell et al 1992; Haupt and Kurz 1993; Teresi and Weiner 1993; Swearer 1994); a prominent risk factor for caregiver burden and psychological morbidity…”
NEUROBEHAVIORAL AND NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER'S DISEASE
Chung, J. A., & Cummings, J. L. (2000) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70228-0 · Cited by 174 · cited 2×
“…of basic and clinical studies, which have suggested that the central cholinergic defi cit associated with AD may be causative for the cognitive deterioration and the neuropsychiatric manifestations of AD (Kaufer et al 1998; Cummings 2000a, 2000b; Cummings et al 2001; Chung and Cummings 2000).”
Cited by
Liss, J. L., Seleri Assunção, S., Cummings, J., Atri, A., Geldmacher, D. S., Candela, S. F., Devanand, D. P., Fillit, H. M., Susman, J., Mintzer, J., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13244 · Cited by 312
Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract
Kongkeaw, C., Dilokthornsakul, P., Thanarangsarit, P., Limpeanchob, N., & Norman Scholfield, C. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.11.008 · Cited by 188
Na, R., Yang, J.-H., Yeom, Y., Kim, Y. J., Byun, S., Kim, K., & Kim, K. W. (2019) · Psychiatry Investigation · doi:10.30773/pi.2019.02.11.2 · Cited by 70
O'Connor, C. M., Clemson, L., Brodaty, H., Jeon, Y. H., Mioshi, E., & Gitlin, L. N. (2014) · International Psychogeriatrics · doi:10.1017/s1041610214000040 · Cited by 27
Combination Drug Therapy for the Management of Alzheimer’s Disease
Dudchenko, N. G., & Mkhitaryan, E. A. (2024) · Russian Journal of Geriatric Medicine · doi:10.37586/2686-8636-2-2024-140-144 · Cited by 2
Metadata
- Authors
- Malaz Boustani, M., Campbell, N., Fox, C., Ayub, A., Farlow, M. R., & Maidment, I.
- Venue
- Clinical Interventions in Aging
- Publisher
- Informa UK Limited
- Published
- 2008-12
- Volume
- Volume 3
- Issue
- 4
- Pages
- 719-728
- ISSN
- 1176-9092 (ISSN-L)
- 1178-1998
- OpenAlex
- W1710626265
- Cited by
- 72
- References
- 12
- FWCI
- 0.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.